NCT02915224 2022-06-28A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesHoffmann-La RocheCompleted50 enrolled